GP (HK) Introduces A Global Innovative Mitral Valve Replacement Medical Device – Saturn, Continue To Deepen The Product Pipeline Strategic Plan In The Field Of Precision Interventional Diagnosis And Treatment 2021-11-28 Corporate News READ MORE
GP (HK)’s Global Innovative Drug STC3141 Successfully Dosed the First Patient of its Phase Ib Clinical Trial for ARDS In China, Deepen the Dual-Cycle Development Strategy and Continues the Global Development Process 2021-11-10 Corporate News READ MORE
GP (HK)’s Global Innovative Drug Ryaltris Compound Nasal Spray Has Been Granted Phase Three Clinical Trial Approval, Enriches the Group’s Product Pipeline, and Consolidates its Competitive Advantage in the field of Respiratory & ENT 2021-10-21 Corporate News READ MORE
GP (HK) Acquires 80% Equity of Huachen BioTech, Accelerating the Globalization Development of Amino Acid Industry 2021-10-19 Corporate News READ MORE
GP (HK) Announces 2021 interim Results, Profit Attributable to Owners of the Company Surges 67.4% to HK$1.2 billion, Continue to Increase R&D Investment, Proposes to Implement a Share Award Scheme 2021-8-11 Corporate News READ MORE
GP (HK) Enters into Strategic Cooperation with CoRISMA on Equity Interests and Products, Introducing a Global Innovative Advanced Heart Failure Therapeutic System, Improving Product Pipeline in the Field of Cerebro-Cardiovascular Precision Interventional Diagnosis and Treatment 2021-8-6 Corporate News READ MORE
GP (HK) Enters into Investment and Strategic Cooperation Agreements with FastWave, a High-end Medical Device Development Company in the United States, Jointly Developing an Innovative Intravascular Shock Wave Calcification Treatment System, Establishing an Overseas R&D Platform for High-end Medical Devices 2021-8-4 Corporate News READ MORE
GP (HK) Announces the Positive Profit Alert, The Consolidated Net Profit Attributable to Owners of the Company for the First Half of 2021 is Expected to Increase Not Less Than 50% 2021-7-28 Corporate News READ MORE
GP (HK)’s Associate OncoSec Enters into A Collaboration Agreement with Merck to Conduct a Global Phase III Study in Advanced Metastatic Melanoma. The R&D of TAVO™ Records Landmark Progress, Continuing to Consolidate the Strategic Planning in Anti-Tumor Immunology Field 2021-7-9 Corporate News READ MORE
GP(HK) Global Innovative RDC TLX250-CDX Dosed the First Patient with the Expanding Indication in Australia, and the Self-developed “Tadalafil Tablets” is Granted a Drug Registration Certificate, Continuously Improving Research Strength and Enriching Its Product Pipelines 2021-7-8 Corporate News READ MORE
GP (HK) Subscribes for New Shares of Sirtex HoldCo and Reaches the TRS Agreements with Natixis. Further Increase Shareholding Rights in Sirtex and Strengthen the Group’s Product Pipeline in the Field of Tumor Precision Interventional 2021-7-2 Corporate News READ MORE
GP (HK) Obtains Exclusive Development and Commercialization Rights of Improved New Drug for Anti-inflammatory and Pain Relief after Ophthalmology Surgery, Enriches Its Product Pipeline of High-Barrier Drugs in the Ophthalmology Sector 2021-6-4 Corporate News READ MORE
English
